News | August 02, 2021
PI Industries acquires API business of Ind Swift Laboratories
Turnover of API division of ISLL stood at Rs 856.58 crore
Turnover of API division of ISLL stood at Rs 856.58 crore
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
The company has already embarked upon significant expansion in Turkey
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The company has a cumulative total of 147 ANDA approvals (129 final approvals and 18 tentative approvals) from USFDA
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Subscribe To Our Newsletter & Stay Updated
